DYN•benzinga•
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact On Multiple Measures Of Myotonic Dystrophy Type 1; Company Plans To Initiate Registrational Expansion Cohort To Support Potential Submission For U.S. Accelerated Approval For DYNE-101 i
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 10, 2025 by benzinga